TLX Stock Analysis: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$9.58
0.01 (0.16%)
▲
5d:
+3.85%
30d:
-11.83%
90d:
+21.66%
BUY
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Jun 18, 2026
2d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 4.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 4.1% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.25
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.09
5.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $9.57, which is considered fair relative to its 30-day fair value range of $9.28 to $10.43. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.6) compared to its historical average (25.4). At these levels, the market is pricing in 4.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is approaching resistance at $9.76. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.83 (+117.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is approaching resistance at $9.76. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.83 (+117.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.28 -
$10.43
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 117.9% below Wall St target ($20.83)
- NEUTRAL: Market pricing in 4.1% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$9.28 -
$10.43
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.69
Resistance Level
$9.76
Current Trend
Strong Downtrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.64
Wall Street Target
$20.83
(+117.9%)
Revenue Growth (YoY)
49.3%
Profit Margin
-0.9%
Valuation Premium vs History
+4.1% premium
PE vs Historical
28.6 vs 25.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.1%
(market-implied from PE analysis)
1-Year Target
$9.95
(+4%)
2-Year Target
$10.36
(+8%)
3-Year Target
$10.78
(+13%)
3-Yr Target (if PE normalizes)
(PE: 29→25)
PE COMPRESSION
$9.56
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.6, Growth: 153.8%)
$32.27
(+238%)
Base:
(SPY PE: 21.9, Growth: 153.8%)
$24.69
(+158%)
Bear:
(PE: 18.6, Growth: 153.8%)
$20.99
(+120%)
Share & Embed Analysis
Last updated: June 15, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 54 HOLD |
